ANTI-CD20 MONOCLONAL ANTIBODY HAVING DIRECT CYTOTOXIC ACTIVITY

Title:

ANTI-CD20 MONOCLONAL ANTIBODY HAVING DIRECT CYTOTOXIC ACTIVITY

Document Type and Number:

Japanese Patent JP2009286719

Kind Code:

A

Abstract:

To provide a humanized anti-CD20 monoclonal antibody having a biological function distinguishable from existing anti-CD20 monoclonal antibody therapeutic drugs.

By specifying a humanized monoclonal antibody which specifically binds to a CD20 positive cell, directly induces apoptosis, and has strong cytotoxicity, an effective therapeutic drug for patients involved in nonreaction to existing therapeutic drugs, recurring B cells or an antibody produced by B cells is developed.

More Like This:

JP2022531141	How to condition gene therapy
JP7008020	Canine humanized antibodies to human and canine IL-4R alpha
JP4330594	New Receptor Tyrosine Kinase and Its Applications

Inventors:

USUDA SADAKAZU
UEMATSU TETSUO
NISHIDA MICHIO
PADLAN EDUARDO A

Application Number:

JP2008139975A

Publication Date:

December 10, 2009

Filing Date:

May 28, 2008

Export Citation:

Click for automatic bibliography generation Help

Assignee:

BIOMEDICS INC
PADLAN EDUARDO A

International Classes:

C07K16/28; A61K39/395; C07K16/46; C12P21/08

Attorney, Agent or Firm:

Yoshiyuki Kawaguchi
Hidemi Matsukura
Tsutomu Toyama

Previous Patent: METHOD FOR PURIFYING (1,3-DIOXORAN-4-YL)ALKYL ALCOHOL

Next Patent: -SUBSTITUTED ACRYLATE DERIVATIVE, AND METHOD FOR PRODUCING THE SAME